CN114364385B - 用于对抗代谢疾病的组合物及其用途 - Google Patents

用于对抗代谢疾病的组合物及其用途 Download PDF

Info

Publication number
CN114364385B
CN114364385B CN202080060415.1A CN202080060415A CN114364385B CN 114364385 B CN114364385 B CN 114364385B CN 202080060415 A CN202080060415 A CN 202080060415A CN 114364385 B CN114364385 B CN 114364385B
Authority
CN
China
Prior art keywords
therapeutic agent
mice
group
shows
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080060415.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114364385A (zh
Inventor
黄仕强
马诗琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Zoology of CAS
Original Assignee
Institute of Zoology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Zoology of CAS filed Critical Institute of Zoology of CAS
Publication of CN114364385A publication Critical patent/CN114364385A/zh
Application granted granted Critical
Publication of CN114364385B publication Critical patent/CN114364385B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080060415.1A 2019-08-30 2020-08-28 用于对抗代谢疾病的组合物及其用途 Active CN114364385B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019103677 2019-08-30
CNPCT/CN2019/103677 2019-08-30
PCT/CN2020/112143 WO2021037212A1 (zh) 2019-08-30 2020-08-28 用于对抗代谢疾病的组合物及其用途

Publications (2)

Publication Number Publication Date
CN114364385A CN114364385A (zh) 2022-04-15
CN114364385B true CN114364385B (zh) 2025-05-27

Family

ID=74683374

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060415.1A Active CN114364385B (zh) 2019-08-30 2020-08-28 用于对抗代谢疾病的组合物及其用途

Country Status (8)

Country Link
US (1) US20220323408A1 (https=)
EP (1) EP4023225B1 (https=)
JP (1) JP7645244B2 (https=)
KR (1) KR20220054351A (https=)
CN (1) CN114364385B (https=)
CA (1) CA3152868A1 (https=)
IL (1) IL290927A (https=)
WO (1) WO2021037212A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3163342A1 (en) * 2019-12-05 2021-06-10 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN116583274A (zh) * 2020-12-14 2023-08-11 医学文库有限责任公司 用于治疗和预防微生物感染性疾病和相关炎性障碍的方法和药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101702884A (zh) * 2007-03-09 2010-05-05 西姆科皮亚公司 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5127093B1 (https=) 1970-11-11 1976-08-10
EP0177574B1 (en) 1984-04-02 1989-12-20 Cornell Research Foundation, Inc. Aminocarnitines
HUT65327A (en) 1992-06-11 1994-05-02 Sandoz Ag Process for producing phosphinyloxy-propyl-ammonium inner sact derwatives ang pharmateutical preparations containing them
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US20110275649A1 (en) * 2010-05-05 2011-11-10 Palmetto Pharmaceuticals Llc Combination therapy for the prevention of statin induced diabetes
EP2654777A4 (en) * 2010-12-21 2014-07-09 Nestec Sa METHOD AND COMPOSITIONS FOR ADMINISTERING THE BLOOD SUGAR IN ANIMALS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101702884A (zh) * 2007-03-09 2010-05-05 西姆科皮亚公司 用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
2型糖尿病与炎症的研究进展;高远等;《中华临床医师杂志( 电子版)》;第4卷(第9期);第1635-1638页 *
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes;Ripudaman S. Hundal等;《The Journal of Clinical Investigation》;第109卷(第10期);第1321-1326页 *
Omar M.E. Abdel-Salam等.Pharmacological Investigation of Trimetazidine in Models of Infl ammation, Pain and Gastric Injury in Rodents.《Pharmacology》.2005,第75卷第122-132页. *
Pharmacological Investigation of Trimetazidine in Models of Infl ammation, Pain and Gastric Injury in Rodents;Omar M.E. Abdel-Salam等;《Pharmacology》;第75卷;第122-132页 *
吕煜等.曲美他嗪联合阿司匹林治疗不稳定型心绞痛82例的临床研究.《中国伤残医学》.2014,第22卷(第10期),第143-144页. *
曲美他嗪联合阿司匹林治疗不稳定型心绞痛82例的临床研究;吕煜等;《中国伤残医学》;第22卷(第10期);第143-144页 *
曲美他嗪联合阿司匹林治疗冠心病 合并心力衰竭患者的临床疗效;王振国;《山西医药杂志》;第48卷(第24期);第3043-3044页 *

Also Published As

Publication number Publication date
IL290927A (en) 2022-04-01
EP4023225A4 (en) 2023-08-30
JP2022546987A (ja) 2022-11-10
AU2020339557A1 (en) 2022-03-24
EP4023225C0 (en) 2026-01-28
EP4023225B1 (en) 2026-01-28
US20220323408A1 (en) 2022-10-13
EP4023225A1 (en) 2022-07-06
CN114364385A (zh) 2022-04-15
CA3152868A1 (en) 2021-03-04
WO2021037212A9 (zh) 2022-03-24
WO2021037212A1 (zh) 2021-03-04
JP7645244B2 (ja) 2025-03-13
KR20220054351A (ko) 2022-05-02

Similar Documents

Publication Publication Date Title
Tahara et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
DeFronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
JP6387010B2 (ja) 血中グルコースレベルを制御することによる糖尿病及び関連容態の処置のための組成物、方法及び使用
Rizos et al. Pleiotropic effects of thiazolidinediones
JP5615805B2 (ja) 細胞ストレス応答の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ
Zhang et al. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
KR20190117632A (ko) Ppar 효현제와 fxr 효현제의 병용
KR20190108141A (ko) 조합 치료요법용 약학 조성물
Yan et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus
Al-Barazanji et al. Synergistic effects of a GPR119 agonist with metformin on weight loss in diet-induced obese mice
CN114364385B (zh) 用于对抗代谢疾病的组合物及其用途
Zhang et al. Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy
Papaetis SGLT2 inhibitors and diabetic kidney disease: targeting multiple and interrelated signaling pathways for renal protection
JP2019532048A (ja) Ｆｘｒアゴニストの新規のレジーム
Li et al. Fenofibrate induces liver enlargement in aging mice via activating the PPARα-YAP signaling pathway
RU2827553C1 (ru) Композиция, используемая для борьбы с метаболическими заболеваниями, и применения композиции
Ren et al. A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro
AU2020339557B2 (en) Composition used for combating metabolic diseases and uses of composition
HK40071125A (en) Composition used for combating metabolic diseases and uses of composition
EP4319734A2 (en) Prostaglandin receptor 3 (ep3) antagonists for use in the treatment of diabetes
Tajima et al. Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes
Trivedi et al. Emerging in Diabetic Cardiomyopathy: Molecular Pathways and Targets for Therapeutic Intervention
CA2512618C (en) Use of r-4-trimethylammonio-3-(tetradecyl-carbamoyl)-aminobutyrate and metformin for the treatment of diabetes
Wang et al. Long-term effects of fenofibrate in male offspring of gestational diabetic rats: Evaluation of glycemia, lipid profiles, liver tissue, and metabolic alternations
JP5634985B2 (ja) インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant